The Latest Breaking News from Kenvue

An unusual number of out-of-the-money put options in Johnson & Johnson come after the Aug. 30 spinoff of its consumer Kenvue business. This could be a good income play for short-put traders.

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

Stock futures mixed as tech sector outlooks dim; Tesla shares slide as Elon Musk signals more EV price cuts; Netflix slumps as blowout subscriber numbers can't offset revenue miss; Johnson & Johnson earnings on deck following Kenvue spin-off and United Airlines shares higher after solid Q2 earnings, outlook lift.

Morningstar gives wide moat ratings to companies it views with competitive advantages that will last at least 20 years.

The IPO market is expected to thrive in the second half of 2023. Deals are getting larger and less volatile.

Johnson & Johnson rips off Band-Aid and spits out Listerine in a bid to boost margins.

Stock futures build gains, Treasury yields rise, with earnings in focus; Netflix nudges higher as investors eye paid sharing effect on profits; Goldman Sachs gains as bank earnings re-take center stage on Wall Street; Johnson & Johnson earnings on deck with Kenvue IPO, talc bankruptcy in focus and Nvidia shares…

The medical industry, which thrived during the pandemic years, is envisioned to remain buoyed despite the economic headwinds, thanks to the inelastic demand the sector faces. Against this backdrop, we think the strong fundamentals of Johnson and Johnson (JNJ) make it a wise portfolio addition. Read on….

Rising anxieties owing to the likelihood of an impending recession have weighed heavily on the stock market. Given the uncertainties are not likely to ease anytime soon, quality stocks Johnson & Johnson (JNJ) and Pfizer (PFE) might be wise portfolio additions to help you keep money in your pockets. Read…